Summary
No substantive AI-generated prescribing claims were provided to evaluate for alignment; the prompt content is mostly FDA excerpts plus a few generic statements, and the evaluation output in the prompt does not clearly map to specific AI claims about Catapres-TTS dosing/safety.
Category Scores
Accurate Statements
Unsupported Statements
Catapres is the brand name for clonidine.
This statement is not supported by the supplied FDA label excerpts for CATAPRES-TTS (transdermal system). The excerpts do not confirm the relationship between Catapres and clonidine as a branded product identity (they mention Catapres in the withdrawal section, but the prompt does not provide label text explicitly stating 'Catapres is the brand name for clonidine.' for Catapres specifically).
Common tablet strengths of clonidine used under the Catapres brand are 0.1 mg and 0.2 mg.
Not supported by the provided label excerpts (which focus on CATAPRES-TTS transdermal patch).
There are other clonidine products in some markets.
Not supported by the provided label excerpts.
Clonidine tablet dosing depends on why it was prescribed (for example, high blood pressure) and on the patient's age, blood pressure response, and other medications.
Not supported for CATAPRES-TTS by the provided excerpts; the excerpts provide CATAPRES-TTS titration guidance for hypertension but do not support this broader statement about 'clonidine tablets' and specific patient factors.
Drug pricing changes by country, pharmacy, insurance, and dose form.
Not supported by the provided FDA label excerpts.
The amount you mean could be either the dose to take or the price.
Not supported by the provided FDA label excerpts.
Catapres should be taken exactly as directed by the prescriber.
Not supported by the provided FDA label excerpts for CATAPRES-TTS.
Contradictions
Important Omissions
No evaluation-ready AI response prescribing claims for CATAPRES-TTS were included beyond generic statements (e.g., application location/rotation, once every 7 days, titration and substitution effects, contraindication for hypersensitivity, withdrawal/avoid abrupt discontinuation, interactions/monitoring).
Importance:
Moderate
Safety Assessment
Potential Patient Risk:
High
Because the only actionable statements concern generic clonidine/Catapres tablet information and unrelated non-label claims (e.g., pricing), there is no on-label guidance verified for the specific product CATAPRES-TTS (patch). This increases the likelihood that an end user could receive incorrect or non-actionable information for the transdermal system.
Regulatory Assessment
| On Label |
No |
| Off-label Discussion |
No |
| Promotes Unapproved Use |
No |
| Hallucination Risk |
Medium |
Recommendation
Not Aligned
Primary Issue
Provided statements are largely not supported by the supplied CATAPRES-TTS FDA label excerpts and do not accurately address on-label transdermal patch dosing/application requirements.
Suggested Improvement
Evaluate and report alignment using specific CATAPRES-TTS claims from the AI response (e.g., apply once every 7 days to upper outer arm or chest; rotate sites; titrate from CATAPRES-TTS-1; substitution effects may not occur until 2–3 days; warnings about not discontinuing abruptly and withdrawal management; contraindication for hypersensitivity; interaction/monitoring guidance).